Sensus Healthcare First Quarter Financial

Sensus Healthcare First Quarter Financial

Results Feature Revenues up 43%

Sixth consecutive quarter of

double-digit year-over-year revenue growth

Conference call begins at 4:30

BOCA RATON, Fla. (May 4, 2017) - Sensus

Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers

and keloids with superficial radiation therapy (SRT), announces financial results for the three months ended March 31, 2017.

Highlights of the first quarter of 2017 and

recent weeks include (all comparisons are with the first quarter of 2016, unless otherwise noted):

Management Commentary

"We had an excellent first quarter as

our revenues reflected continued sales momentum and growing acceptance of SRT for the treatment of non-melanoma skin cancer and

keloid scars," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "We also increased our

investment in sales and marketing, adding three individuals to our sales organization bringing the total to 20. We expect to have

30 sales representatives by the end of the year. While I am pleased with our progress toward this goal, I am even more pleased

with the professionalism, dedication and enthusiasm our sales and marketing staff is bringing to Sensus. They recognize the benefits

of SRT to patients, physicians and third-party payors and are driven to spread the word about the benefits of this treatment option.

During the quarter we participated in a number of important conferences and industry trade shows, with Key Opinion Leaders presenting

work supporting the use of SRT. We are also making progress with in-hospital radiation oncology sales.

"Research and development remains an

important driver for our growth in 2018 and beyond, and we have stepped up our activities to broaden the use of SRT to additional

indications and to provide a next-generation product to our customers," Mr. Sardano added. "We have qualified several

sites to begin psoriasis studies with the SRT-100 Vision, and are on schedule with our development of intraoperative radiation

therapy (IORT) for the treatment of breast and other cancers. We expect our investment in these activities to have a positive financial

impact on the Company in 2018 and beyond.

"Our international expansion is proceeding

as planned. Building upon our clearance for SRT-100 in the important China market, we are making progress towards securing clearance

in China for treating and preventing keloid scars. We also recently installed a second unit in Israel at a highly-regarded medical

center, and view this as further validation for the use of our SRT systems. We have applied for regulatory clearance in Mexico

for the SRT-100, and expect to begin marketing there later this year."

Mr. Sardano concluded, "The first quarter

was the sixth consecutive quarter of double-digit year-over-year revenue growth, and we expect this growth to continue as we progress

Revenues for the first quarter of 2017 increased

43.5% to $4.4 million, compared with $3.0 million for the first quarter of 2016. The increase was primarily the result of a strong

contribution from the SRT-100 Vision, which has a higher average selling price.

Gross profit for the first quarter of 2017

was $2.9 million, or 65.6% of revenue, compared with $1.9 million, or 63.7% of revenue, for the first quarter of 2016. Both gross

profit and gross margin were positively affected by the contribution of SRT-100 Vision systems.

Selling and marketing expenses were $2.3 million

for the first quarter of 2017, compared with $1.0 million for the first quarter of 2016, due to increased sales team headcount

as well as higher advertising, trade show expenses and other marketing costs.

General and administrative expenses for the

first quarter of 2017 were $1.0 million, compared with $0.7 million for the first quarter of 2016 primarily due to public company

expenses following the company's initial public offering in June 2016.

Research and development expenses for the first

quarter of 2017 were $1.1 million, compared with $0.3 million for the first quarter of 2016 primarily due to the continued investment

in the next-generation SRT and IORT projects that began in the fourth quarter of 2016.

Net loss for the first quarter of 2017 was

$1.6 million, or ($0.12)) per share, compared with net income of approximately $2,000, or $0.00 per share for the first quarter

Adjusted EBITDA for first quarter of 2017 was

$(1.4) million, compared with $0.1 million for the first quarter of 2016. Adjusted EBITDA is defined as earnings before depreciation

and amortization, income taxes, interest expense and stock compensation expense. Please see below for a reconciliation between

GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial measures are provided.

Cash, cash equivalents and investments were

$11.0 million as of March 31, 2017.

Use of Non-GAAP Financial Information

This press release contains supplemental financial

information determined by methods other than in accordance with accounting principles generally accepted in the United States of

America ("GAAP"). Sensus Healthcare's management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis

of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures nor should it be viewed as a substitute

for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes

the impact of interest expense, income taxes, depreciation, amortization and stock compensation expense, provides useful supplemental

information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures

are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare.

As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice

of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort

comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

SENSUS HEALTHCARE, INC.

GAAP TO NON-GAAP RECONCILIATION

Conference Call and Webcast

As previously announced, the Company will host

an investment community conference call today at 4:30 p.m. Eastern time, during which management will discuss financial results

for the first quarter of 2017, provide a business update and a discussion on recent and upcoming milestones. To access the conference

call, the dial-in numbers are 1-877-870-4263 (U.S. Toll Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll Free).

Please ask the operator to be connected to the Sensus Healthcare call.

Following the conclusion of the conference

call, a replay will be available through May 11, 2017 and can be accessed by dialing 1-877-344-7529 (U.S. Toll Free), 1-412-317-0088

(International), and 1-855-669-9658 (Canada Toll Free). All listeners should provide the replay passcode 10106354. The call will

also be archived on the Company website for a time at http://www.sensushealthcare.com

Forward-Looking Statements

This press release includes statements that

are, or may be deemed, ''forward-looking statements.'' In some cases, these forward-looking statements can be identified by the

use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects,"

"plans," "intends," "may," "could," "might," "will," "should,"

"approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology,

although not all forward-looking statements contain these words.

By their nature, forward-looking statements

involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific

developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter

timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in

this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual

results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially

from the forward looking statements contained in this press release, as a result of, among other factors: our ability to achieve

and sustain profitability; market acceptance of the SRT-100 product line; our ability to successfully commercialize our products,

including the SRT-100; our ability to compete effectively in selling our products and services, including responding to technological

change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future, as well

as complying with the restrictions our existing revolving credit facility imposes; our ability to expand, manage and maintain our

direct sales and marketing organizations; our actual financial results may vary significantly from forecasts and from period to